Table 1 Patient characteristics
No. of patients (n = 29) (%) | |
|---|---|
Age | 50.6 ± 9.0 |
Symptom | |
No (abnormal screening) | 21 (75.0) |
Yes (palpable or discharge) | 7 (25.0) |
Clinical stage | |
IIA | 3 (10.3) |
IIB | 7 (24.1) |
IIIA | 18 (62.1) |
IIIC | 1 (3.5) |
Chemotherapy regimen | |
AC | 9 |
AT | 20 |
Operation method | |
BCS | 6 (20.7) |
Mastectomy | 23 (79.3) |
Histologic type | |
IDC | 27 (93.1) |
ILC | 1 (3.5) |
Mucinous carcinoma | 1 (3.5) |
Histologic grade | |
Grade 1 or 2 | 18 (62.1) |
Grade 3 | 11 (37.9) |
ER status | |
(+) | 11 (37.9) |
(−) | 18 (62.1) |
PR status | |
(+) | 14 (48.3) |
(−) | 15 (51.7) |
HER2 status | |
(+) | 11 (37.9) |
(−) | 18 (62.1) |
Molecular subtypes | |
Luminal | 18 (62.1) |
HER2-enriched | 10 (34.5) |
Triple negative | 1 (3.4) |
Clinical response by MG | |
PR | 5 (17.2) |
SD | 23 (79.3) |
PD | 1 (3.4) |
Clinical response by MRI | |
CR | 6 (20.7) |
PR | 18 (62.1) |
SD | 5 (17.2) |
Pathological response | |
pCR | 4 (13.8) |
Non-pCR | 25 (86.2) |